Everett Collection / Shutterstock.com
At first glance, it might seem odd for a company to both divide blood plasma and fight the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP.
During World War II, as soldiers struggled to cope with injuries sustained in battle, a man called Edwin Cohn created a solution to help them recover.
The scientist invented the first practical method of what is known as blood plasma fractionation, where the conditions of pooled plasma (for example, temperature or acidity) are changed so that proteins that are normally dissolved become insoluble, aiding a speedy recovery.
At the time, the method, known as the Cohn process, was hailed as revolutionary. But fast-forward 70 years and a US company thinks it has found a new solution that will be a game-changer, and has patented it.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
PlasmaTech; pharmaceuticals; trade secrets